Rosettearray platform for discovering nutritional prophylactics for neurodevelopmental disorders

Overview

Neurosetta offers a proprietary stem cell-based screening platform, RosetteArray, that models early human neural tube morphogenesis in a scalable, high-throughput format. The platform enables researchers to evaluate developmental neurotoxicity and detect genetic and environmental risk factors for neurodevelopmental disorders such as Autism Spectrum Disorder (ASD) and Spina Bifida (SB). By using RosetteArrays derived from human pluripotent stem cells carrying ASD- and SB-associated genetic risk mutations, the platform can be applied to screen for novel nutritional supplements that may lower a mother's risk of a disorder-afflicted pregnancy or mitigate ASD severity in affected children. With ASD affecting an estimated 1 in 36 children in the United States and over 3,000 U.S. births annually affected by SB, this approach addresses significant unmet needs in maternal and child health.

Technical specifications

• RosetteArray platform: A micropatterned well plate system that uses specialized surface chemistry to induce the formation of neural rosettes from human pluripotent stem cells or neuromesodermal progenitors, reproducing early human neurodevelopment in vitro.
• High-throughput screening: Scalable format suitable for screening libraries of approximately 1,000 compounds per disorder, with screening durations of 6 to 12 months.
• Personalized disease modeling: Can be tailored to patient-derived stem cell lines with specific genomic backgrounds, including SYNGAP1 mutations for ASD and MTHFR and SCRIB mutations for SB, improving the likelihood of clinical success.
• Validated assays: Demonstrated ability to detect clinically relevant positive and negative controls, including known risk-associated compounds such as Dolutegravir, and to identify risk phenotypes in gene-edited lines.
• Deliverables: Single-dose data for all tested compounds and dose-response data for putative prophylactics.
• Intellectual property: Patented technology (USPTO #US-11767508-B2) with published peer-reviewed validation.

Technology readiness level

The RosetteArray platform has been published in a peer-reviewed journal and patented. Its utility as a diagnostic for SYNGAP1-associated ASD is forthcoming in a leading neuroscience journal. The platform has been validated with clinically relevant controls and gene-edited human pluripotent stem cell lines for both ASD and SB risk detection. Current activities focus on applying the platform to discover novel prophylactic uses for known and newly developed nutritional compounds, with milestone-based screening programs underway. The technology is commercially available through standardized assays and custom service engagements with pharmaceutical, chemical, and research organizations.